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Poststroke chronic disease management: towards
improved identification and interventions for poststroke
spasticity-related complications
Michael Brainin1, Bo Norrving2, Katharina S. Sunnerhagen3, Larry B. Goldstein4,
Steven C. Cramer5, Geoffrey A. Donnan6, Pamela W. Duncan7, Gerard Francisco8,
David Good9, Glenn Graham10, Brett M. Kissela11, John Olver12, Anthony Ward13,
Jo¨rgWissel14, and Richard Zorowitz15, on behalf of International PSS Disability Study Group
This paper represents theopinionof a groupof researchers and
clinicians with an established interest in poststroke care and is
based on the recognised need for long-term care following
stroke, especially inviewof theglobal increaseofdisabilitydue
to stroke. Among the more frequent long-term complications
following stroke are spasticity-related disabilities. Although
spasticity alone occurs in up to 60% of stroke survivors,
disabling spasticity affects only 4–10%. Spasticity further inter-
feres with important functions of daily life when it occurs in
association with pain, motor impairment, and overall declines
of cognitive and neurological function. It is proposed that the
aftermath of stroke be considered a chronic disease requiring a
multifactorial and multilevel approach. There are, however,
knowledge gaps related to the prediction and recognition of
poststroke disability. Interventions toprevent orminimise such
disabilities require further development and evaluation. Post-
stroke spasticity research should focus on reducing disability
and be considered as part of a continuum of chronic care
requirements and should be recognised as a part of a compre-
hensive poststroke disease management programme.
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Introduction
The burden of stroke is increasing on a global scale and the
associated long-term disability is also rising. Annually, 15
million people worldwide have a stroke. Five million die and
another 5 million are left permanently disabled (1), with
complications including motor (50–83%), cognitive (50%),
and language impairments (23–36%) (2); poststroke seizures
(10%) (3); neuropathic pain (8%) (3); and psychological
disturbances (20%) (2). Estimates indicate that 33–42% of
patients still require assistance for daily living activities three–
six-years poststroke, and 36% of patients remain disabled after
five-years (4). Stroke and its subsequent disabilities place a
large burden on the family and community (1), accounting for
approximately 2–4% of total health care costs globally (5) with
a lifetime cost estimated at US$1 40 048 in the United States
and 43 129 in Europe (3).
The global prevalence of stroke is increasing (2). Based on
data from the World Health Organization (1), survival time
after a first stroke may be as low as two–three-years in regions
such as Africa or Southeast Asia, whereas in the United States,
the median survival time ranges from approximately six- toDOI: 10.1111/j.1747-4949.2010.00539.x
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eight-years for patients older than 60-years (6). One-third of
stroke patients are under the age of 65 (7), which has important
implications as younger patients may live with disabilities for
even longer periods. Despite these facts, the long-term impact
of stroke and the availability of health care services remain
largely unassessed within the global context (8). Although
studies have evaluated short-term poststroke outcomes, such
as motor impairments, cognitive dysfunctions, and language
difficulties (2), longer term stroke follow-up studies focus
primarily on mortality (9). The long-term impact on stroke
caregivers is poorly understood, although short-term data
suggest that caregivers suffer from higher rates of emotional
and physical symptoms compared with noncaregivers (10, 11).
With approximately one-third of the treatment cost of stroke
attributable to rehabilitative care, the economic implications of
chronic poststroke disability may be considerable (9, 12). Thus,
stroke chronic disease management should be recognised as a
public health priority by governments and health authorities.
Some evidence-based guidelines are available; however, their
application varies. There is a need to establish how more
consistent application of current guidelines can improve stroke
recovery andoutcomes. For example,models exist for improving
stroke systems of care (13–15); however, successful implementa-
tion of these guidelinesmaybe hamperedby a numberof factors,
including lack of adherence to guidelines and policies (16),
limited access to resources and stroke care facilities (17–20), and
variability in provider education and skills (17, 19, 21). It may
also be difficult to assess the efficacy of patient adherence to
recovery strategies once patients have left the hospital.
High-quality stroke care represents a continuumcomprising
primordial/primary prevention, acute/emergency care, recov-
ery and rehabilitation, and secondary prevention (12). There
are several gaps in the continuumwithin ‘organised’ systems of
stroke care that may contribute to suboptimal patient out-
comes. First, few patients admitted to hospitals for acute stroke
receive care in a specialised stroke unit. A recent study showed
that only 85% of stroke patients in Europe received care at
comprehensive or primary stroke centres (22). In low-income
countries, this number is likely even lower. A review of stroke
care in developing countries reported that the number of stroke
units per 100 million people ranged from approximately three
to 30 (17). Although vascular neurologists are an important
part of poststroke management, they are involved to varying
degrees throughout the continuum, and may have limited
interaction with patients after acute hospitalisation. In the
United States, o40% of stroke victims receive care from a
board-certified neurologist and much fewer from a board-
certified vascular neurologist (23).
Another significant challenge to the continuumof stroke care
occurs during long-term recovery. Patients are often advised
after 6–12-months that they have reached a plateau in their
recovery, and it is not uncommon for insurance providers to
stop reimbursement once patients fail to demonstrate func-
tional improvements in response to continued treatment (24).
In addition, these practicesmay conditionpatients not to expect
further recovery once this ‘plateau’ is reached, causing them to
give up and thereby preventing them from achieving even
greater functional gains (24). Both patients and physicians
should be aware that stroke is a chronic disease that should be
managed on a continual basis in order to sustain functional
gains and address new problems that may arise.
Stroke survivor, caregiver, and health care professional mo-
tivation and empowerment are essential to achieving improve-
ments in the continuum of care. Despite the perception that
patients reach a limit in their recovery within 6–12-months,
results from several studies suggest that these plateausmay not
be caused by patients’ reduced capacity formotor recovery, but
by adaptive states that occur as patients becomephysiologically
accustomed to rehabilitation exercises (24). Some studies,
although with small numbers of patients, have indicated that
chronic stroke patients can exhibit continued motor improve-
ment with novel rehabilitation protocols (24). Patients and
stroke care providers should be proactive about continually
seeking new ways to enhance recovery.
One well-known consequence of stroke is poststroke spas-
ticity (PSS), which is defined as a velocity-dependent hyper-
excitability of muscles to stretch and is characterised by
exaggerated deep tendon reflexes, increased resistance to
passive movement, and hypertonia resulting from loss of
upper motor neuron inhibitory control (25). It is well recog-
nised that PSS impacts chronic poststroke disability (26). The
PSS may interfere with motor and activity performance, cause
pain, and lead to secondary complications, such as contracture
or weakness, which may further contribute to poststroke
disability (26). The prevalence and impact of PSS and related
complications are not well understood, and epidemiological
data regarding PSS are limited.
PSS-related complications
It is likely that PSS-related complications are not due to
spasticity alone and that other factors contribute to its impact
(26). Pain and deformity associated with spasticity can increase
disability (e.g., reducedmobility, self care, and ease of hygiene),
increase complications (e.g., pressure sores), and create a
vicious cycle of poor posture that may exacerbate the spasticity
(27). Uncontrolled spasticity can lead to permanent contrac-
ture in the muscles and soft tissues (27). Weakness results from
a loss inmuscle strength due to uppermotor neuron syndrome,
whereas contracture can arise as a result of joint,muscle, or soft
tissue limitations (28). Careful evaluation is therefore required
to establish the cause of the patient’s disabilities before deciding
on the best rehabilitation approach.
Clinicians often focus on the direct effects (i.e., impairment)
of PSS, such as increased muscle tone, rather than indirect
effects (i.e., limitation of activities) that more importantly
impact daily functioning and quality of life. For example,
direct effects include the inability to open the hand, whereas
indirect effects include an impaired ability to grip objects or
clean the hand. This presents challenges to the identification
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and treatment of PSS. The PSS-related complications may
interfere with a variety of functional activities, such as cleaning
hands, dressing, or eating; personal responsibilities, such as
housework or childcare; and workplace activities (29). Even
among those deemed ‘recovered’ from stroke based on a
Barthel index score of Z95, they still can have difficulties
with hand function, dependence in daily activities, impaired
overall physical function, and limitations of social participa-
tion, all of which may impair quality of life (30). Clinical
measures alone underestimate the impact of PSS on patients’
functioning and quality of life, and clinicians should therefore
seek to understand the patient’s condition in terms of PSS-
related complications or disabling PSS. Additionally, efforts
should focus on educating patients, caregivers, and clinicians
on indirect effects and secondary complications associated
with PSS and their impact on rehabilitation and recovery.
Areas that need further research
There is currently an unmet need for an increased under-
standing of PSS and related disabilities. In particular, there is a
need to better understand specific PSS-related complications
within the context of the following domains:
The proportion of patients who experience
PSS-related complications
The prevalence of PSS ranges from as low as 1% (26) to as high
as 60% (31) depending on the poststroke population assessed.
One cohort study (32) reported that 39% of patients with first-
ever stroke are spastic after 12-months, while another study
(33) reported a prevalence of 17% for spasticity and 4% for
disabling spasticity one-year after stroke. The overall preva-
lence of PSS-related complications, however, has not beenwell
studied. There is a clear need for further data to define and
identify the prevalence of PSS and its complications.
The onset time of PSS-related complications
It is recognised that a lag may exist between stroke and the
onset of PSS; however, few studies have investigated the time to
onset of either PSS or its related complications. One study (26)
of 95 patients with first-ever stroke (26) found that 21% were
initially (mean, 54-days) spastic according to the modified
Ashworth Scale, while 19% were spastic three-months after
stroke. Some of the patients who were spastic at three-months
developed spasticity after the initial evaluation (26). Further
research is needed to aid clinicians in anticipating the onset of
spasticity and other common complications following stroke.
How quickly PSS-related complications stabilise
A cohort study (34) evaluating the recovery of motor function
after stroke found the most dramatic improvement occurred
during the first 30-days regardless of the initial severity of the
stroke, although patients with moderate and severe strokes
continued to recover for 30–90-days after the stroke. Spasticity
is generally thought to reach its maximum one–three-months
after stroke (26); however, functional scales may be insensitive
to further improvements (35) and additional research is
needed to better define PSS stabilisation.
Whether PSS is helpful in some patients
Anecdotal examples suggest that PSS may benefit some
patients with underlying muscle weakness; however, as yet
the circumstances in which spasticity may be a positive
phenomenon is not clear (36). Some patients, such as those
with poor lower limb tone (36) or upper motor neuron
weakness (27), may benefit from the increased tone associated
with spasticity, helping them to improve their posture and
maintain or improve their ability to stand and walk. Further
research is needed to clarify the potential benefits associated
with PSS, in contrast to the large evidence base supporting the
need to identify and treat disabling PSS when it occurs.
Identification and diagnosis
Early intervention may reduce the development of spasticity
after stroke (37) and early identification of high-risk patients is
essential. Therefore, factors that predict which patients are at
high risk for development of PSS should be identified. Recent
research has proposed a Cox linear regression model (36) that
predicts the presence of clinically detectable spasticity at 12-
months poststroke (36). The model incorporates data routi-
nely collected following admission for acute stroke, including
prestroke Rankin Scale score, age, gender, urinary continence
at day 7, presence of hemiplegia at admission, and smoking
status. Themodel had both a sensitivity and specificity of 77%,
a positive predictive value of 65%, and a negative predictive
value of 86%. Another model (37) found that a low day 7
Barthel index score combined with early arm or leg weakness
was associated with some spasticity at 12-months after stroke,
whereas low day 7 Barthel index score combined with left-
sided weakness and smoking status were associated with more
severe spasticity at 12-months. Further prospective testing is
required to establish the validity, reliability, and utility of these
and other models, and to determine if incorporating addi-
tional data could improve their predictive value.
Individual measures of PSS and its related complications
may also help to facilitate earlier identification and interven-
tion. Unfortunately, there is no simple measure of PSS.
Neurophysiological measures, such as H-reflex, F-wave, or
muscle response to externally imposed perturbation, can only
measure specific aspects of spasticity (38). Biomechanical
measures provide an indirect assessment by quantifying stiff-
ness, posture at rest, and range of movement. Spasticity is
detected clinically by an increased response to passive move-
ment (36), and in the research setting by clinical measures such
as the Tardieu method, the Ashworth Scale, the Rankin Scale,
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and the Barthel index, among others; however, these measures
also have limitations (38). The Ashworth Scale (38) is com-
monly used tomeasure the severity of spastic hypertonia, but it
has limited clinical relevance because it does not measure PSS-
related complications. The Tone Assessment Scale (36) allows
assignment of a global spasticity score that incorporates
response to passive movement, resting posture, and associated
reactions, but it has not yet demonstrated reliability. The Stroke
Impact Scale (4) measures impairment, disability, handicap,
and quality of life as a result of stroke, but it has not been tested
in a population-based setting for long-term outcomes.
Ideally, measures of PSS-related complications should be
based on individualised patient goals, and may include func-
tion, symptoms, postural assessments, and quality of life
measures. Measures including assessment of daily living
activities and quality of life may also help to motivate payers
and ensure patient access to treatment. Although some studies
find weak or moderate associations between spasticity and
activity performance or health-related quality of life (26, 39),
tools for identifying disabling spasticity with a need for
interventions remain scarce (33).
Treatment of PSS
The decision to treat should depend on the individual patient’s
needs. Poststroke spasticity may have nondisabling effects in
some patients and even be helpful effects in others; for
example, patients with underlying muscle weakness may
benefit from improved posture and the ability to sit upright
(36). The PSS should be treated when it interferes with daily
living activities and/or function, such as maintaining personal
hygiene, dressing, writing, and social/interpersonal issues.
Opportunities for improving the management of PSS-
related disability include treatment of spasticity itself as well
as complications associated with PSS. There are a large variety
of treatment options, including physical and occupational
therapy, electromagnetic stimulation, casting, and pharma-
cotherapy (systemic and focal) (28, 36). Additionally, better
clinical outcomes have been noted when postacute stroke
patients receive coordinated, multidisciplinary intervention
involving a physician, nurse, physical therapist, occupational
therapist, kinesiotherapist, speech and language pathologist,
psychologist, recreational therapist, and family/caregivers
(14). Because of the complexity of treatment, additional data
are needed to establish how treating PSS improves related
functional and quality of life issues.
Treatment should address exacerbating factors such as
infection, pain, constipation and other nociceptive influences,
and careful positioning throughout 24 h to maintain muscle
length and reduce deformity (27, 28). Physiotherapy pro-
grammes aim to improve motor performance partly through
manipulation of muscle tone and typically includes stretching
and/or contraction ofmuscles in the limbs andmaintenance of
joint movement (27, 28). For some patients, physiotherapy
may also include casting or splinting to maintain muscle
stretch and the use of heat or cold to reduce spasticity (28).
Electrical stimulation produces short-lived reductions in spas-
ticity and improves walking for some patients. Evidence for
antispastic effects of electric stimulation is limited and studies
indicate it may be most beneficial when combined with focal
pharmacologic therapies, such as botulinum toxin (28). In
cases of established contracture, surgical release may correct
deformity and facilitate better postures (e.g., standing) to
prevent further spasticity (27, 28).
Systemic antispasmodic drugs (e.g., baclofen, diazepam,
dantrolene, and tizanidine) may also be used to reduce
spasticity (27, 40). These drugs produce generalised muscle
weakness, potentially reducing muscle tone (27, 28). Other
agents with potential benefit include clonidine, cannabis, oral
delta-9-tetra-hydrocannabinol, and gabapentin, although ad-
ditional research evaluating these agents for PSS is needed (40).
Because of the limitations of other pharmacologic agents,
treatment policies have changed towards increasing use of
intramuscular botulinum toxin, which currently is considered
the treatment option of choice for upper limb focal spasticity
based on the strong evidence base (33, 41). In a prospective
trial, comprehensive focal spasticity management including
botulinum toxin and physiotherapy improved patients’ per-
ceived health-related quality of life and motor functions (42).
The PSS-related disability, such as poor hand function,
involves both spasticity and weakness and needs to be ad-
dressed using a combination approach (35). For example,
although spasticity is often thought to be the cause of reduced
wrist and finger extension with some preservation of flexion,
poor motor control with weakness is typically the actual
primary cause of disability (26). Treatment with botulinum
toxin in arm muscles reduces excessive flexion and associated
pain, spasms, or postures that interfere with patients’ self-care
(35, 43); however, in contrast to other spasticity agents (27),
botulinum toxin does not induce muscle weakness (35, 43).
One other study (44), botulinum toxin did not enhance
improvement of upper limb function within 12-months in
poststroke upper extremity therapy or change spasticity in a
significantly measurable way. Optimal therapy for PSS and
related complications should generally involve a combination
of therapeutic approaches to address the diverse aspects of
physical disability and impairment.
In summary, poststroke chronic disease management is a
multifactorial and multilevel process with large regional
variations and unmet needs around the globe. Strongly
influenced by stroke severity, location of the stroke within
the brain, concomitant neurological deficits, and resulting
disability, it is further affected by individual and social traits as
well as socioeconomic determinants. Among thesemany factors,
spasticity-related complications deserve special attention.
Poststroke spasticity has a significant impact on long-term
disability, although gaps in knowledge and recognition of the
symptoms remain.Abetter understandingof the prevalence and
time to onset of PSS-related complications and the establish-
ment of clinically useful measures of PSS that incorporate its
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impact on daily functioning and quality of life are needed.
Management of patients with PSS should focus on the disability
produced by PSS, not simply the spasticity itself, and will
therefore generally integrate multiple therapeutic approaches.
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